Second-line chemotherapy in patients with primary unknown cancer

被引:0
作者
Makiko Ono
Masashi Ando
Kan Yonemori
Harukaze Yamamoto
Taizo Hirata
Chikako Shimizu
Kenji Tamura
Noriyuki Katsumata
Yasuhiro Fujiwara
机构
[1] National Cancer Center Hospital,Breast and Medical Oncology Division
来源
Journal of Cancer Research and Clinical Oncology | 2011年 / 137卷
关键词
Unknown primary site; Chemotherapy; Second-line treatment; Chemotherapy-free interval;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:1185 / 1191
页数:6
相关论文
共 149 条
[1]  
Briasoulis E(2000)Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic cooperative oncology group study J Clin Oncol 18 3101-3107
[2]  
Kalofonos H(2008)Cancers of unknown primary site: ESMO clinical recommendation for diagnosis, treatment and follow-up Ann Oncol 19 ii106-107
[3]  
Bafaloukos D(2008)Gene expression profiling may improve diagnosis in patients with carcinoma of unknown primary Br J Cancer 98 1425-1430
[4]  
Samantas E(2001)5-fluorouracil and leucovorin as second-line chemotherapy in carcinomas of unknown primary site Anticancer Res 21 1455-1457
[5]  
Fountzilas G(1993)Treatment of patients with cancer of an unknown primary site N Engl J Med 329 257-263
[6]  
Xiros N(2001)Gemcitabine in the second-line therapy of patients with carcinoma of unknown primary site: a phase II trial of the Minnie Pearl Cancer Research Network Cancer Invest 19 335-339
[7]  
Skarlos D(2005)Combination chemotherapy with gemcitabine and irinotecan in patients with previously treated carcinoma of an unknown primary site: a Minnie Pearl Cancer Research Network Phase II trial Cancer 104 1992-1997
[8]  
Christodoulou C(2007)Phase II trial of bevacizumab and erlotinib in carcinomas of unknown primary site: the Minnie Pearl Cancer Research Network J Clin Oncol 25 1747-1752
[9]  
Kosmidis P(2008)Gene expression profiling to identify the histogenetic origin of metastatic adenocarcinomas of unknown primary J Clin Oncol 26 4435-4441
[10]  
Pavlidis N(2008)S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial Lancet Oncol 9 215-221